Global EditionASIA 中文雙語Fran?ais
    China
    Home / China / Health

    China approves novel homegrown flu drug

    By Wang Xiaoyu | China Daily | Updated: 2025-06-11 09:10
    Share
    Share - WeChat

    China's top drug regulator has approved a homegrown flu treatment that acts on a novel protein target, adding to the arsenal of weapons against the infectious disease that kills hundreds of thousands of people worldwide each year.

    The first-in-class innovative medicine, onradivir, has been authorized for treating adult patients with uncomplicated influenza A, the National Medical Products Administration said in a statement last month.

    It was jointly developed by Raynovent in Guangzhou, Guangdong province, the First Affiliated Hospital of Guangzhou Medical University, and top respiratory disease research institutions.

    "The approval of this medication provides patients with a new treatment option," the administration said.

    According to the company, the medicine is the world's first anti-influenza drug that targets a protein of the virus's RNA polymerase called PB2. "The new medicine features rapid, potent and low-resistance efficacy and offers a Chinese solution to tackling global influenza epidemics," the company said.

    The medicine, administered as a 0.6-gram tablet, is recommended to be taken in three doses daily for five consecutive days.

    Globally, there are about 1 billion influenza cases, including 3 to 5 million severe cases, leading to 290,000 to 650,000 deaths annually.

    Zhong Nanshan, an academician with the Chinese Academy of Engineering and a renowned respiratory expert, said during an event on Tuesday that onradivir can quickly alleviate symptoms and suppress the viral load to a very low level within 24 hours, making it less likely for the virus to transmit.

    "At the same time, the drug also shows a low tendency to develop resistance," Zhong, who is involved in the drug's development, was quoted by Nanfang Media Group, a local media outlet in Guangdong province, as saying.

    Li Tongzeng, chief physician at Beijing You'an Hospital who was not involved in the research, said that the approval of onradivir marks China's fourth approved anti-influenza drug.

    Studies show that the new drug acts faster than the two most commonly used flu treatments on the market — oseltamivir and baloxavir marboxil — in easing symptoms and reducing viral load in patients.

    "Because onradivir targets a different mechanism than the other two drugs, it should theoretically remain effective even in cases where resistance develops in patients," he said. "When the next flu season arrives, we'll have another weapon in our hands."

    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
     
    亚洲AV无码乱码在线观看| 综合无码一区二区三区| 中文字幕国产精品| 色综合久久无码中文字幕| 日本中文字幕一区二区有码在线| 日韩国产成人无码av毛片 | 蜜臀精品无码AV在线播放| 亚洲日韩激情无码一区| 一本一道AV无码中文字幕| 国产午夜无码精品免费看| 亚洲精品无码AV人在线播放| 亚洲国产精品狼友中文久久久| 久久亚洲中文字幕精品一区| 97性无码区免费| 无码国产精品一区二区免费式芒果| 中文字幕不卡亚洲| 久久五月精品中文字幕| 婷婷综合久久中文字幕| 亚洲一区无码精品色| 亚洲Av无码乱码在线znlu| 2021国产毛片无码视频| av大片在线无码免费| 久久午夜伦鲁片免费无码| 无码专区久久综合久中文字幕| 在线精品无码字幕无码AV| 最新中文字幕AV无码不卡| 国产综合无码一区二区辣椒| 中文字幕亚洲一区| 中文字幕性| 国产成人无码精品久久久性色| 一夲道DVD高清无码| 中文字幕在线免费看线人| 亚洲精品无码AV中文字幕电影网站 | 午夜无码中文字幕在线播放 | 亚洲gv天堂无码男同在线观看| 免费AV一区二区三区无码| 无码av中文一二三区| 中文无码喷潮在线播放| 全球中文成人在线| 久久精品aⅴ无码中文字字幕重口| 狠狠躁夜夜躁无码中文字幕 |